-+ 0.00%
-+ 0.00%
-+ 0.00%

ADMA Biologics publishes 2025 annual report

PUBT·04/16/2026 12:08:38
Listen to the news
ADMA Biologics publishes 2025 annual report
  • ADMA Biologics annual report for fiscal year ended Dec. 31, 2025 highlighted continued commercial momentum for ASCENIV, supported by broader prescriber adoption.
  • FDA cleared yield-enhancement manufacturing process in April 2025, positioning company to lift output from existing plasma volumes heading into 2026.
  • Management pointed to further margin expansion potential in 2026 as yield-enhanced production moves into its first full year.
  • Plasma sourcing strategy shifted toward longer-term third-party supply, expanding access to plasma from more than 280 collection centers.
  • Pipeline update centered on SG-001, with pre-IND package submission planned for 2026 to support potential progression into a registrational trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.